S&P Futures
4,145.00 +14.50 (+0.35%) Dow Futures
34,109.00 +114.00 (+0.34%) Nasdaq Futures
12,602.75 +57.50 (+0.46%) Russell 2000 Futures
1,957.50 +7.60 (+0.39%) Crude Oil
78.53 +0.06 (+0.08%) Gold
1,892.10 +1.40 (+0.07%)
Swisscanto AST Responsible Global Convertible CHF hedged NT CHF (0P00012DKE.SW)
| Previous Close | 126.79 |
| YTD Return | 4.56% |
| Expense Ratio (net) | 0.00% |
| Category | Convertible Bond - Global, CHF Hedged |
| Last Cap Gain | N/A |
| Morningstar Rating | ★★★★★ |
| Morningstar Risk Rating | N/A |
| Sustainability Rating |
| Net Assets | 39.04M |
| Beta (5Y Monthly) | N/A |
| Yield | N/A |
| 5y Average Return | N/A |
| Holdings Turnover | N/A |
| Last Dividend | N/A |
| Average for Category | N/A |
| Inception Date | Apr 08, 2013 |
- PR Newswire
Provention Bio Announces the Grant of Inducement Awards
Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to eight new employees to purchase an aggregate of 166,000 shares of common stock. The stock options were granted without stockholder approval as inducements, material to the new employees entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4) and were approved by t
- PR Newswire
Provention Bio to Present at the Jefferies Global Healthcare Conference
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a corporate presentation at the Jefferies Global Healthcare Conference on Wednesday, June 8th 2022 at 9:00 am EST in New York City.
- PR Newswire
Provention Bio Announces Update to Board of Directors
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced Dr. Jeffrey Bluestone's decision to step down as a director on the Company's board of directors to focus on his other commitments, including his role as President and Chief Executive Officer of Sonoma Biotherapeutics. Dr. Bluestone will continue as Scientific Advisor to the Company.
